Project Grant R01AG102790
Award Date 8/15/26
Completion Date 7/31/31
Dollars Obligated $721K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Arkansas, USA
Similar Awards
- The National Institute on Aging awarded Mayo Clinic $443,850 on March 15, 2026, under the Aging Research program (CFDA 93.866) to study the real-world effects of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications on older adults. Mayo Clinic will use linked electronic health records from the Rochester Epidemiology Project to analyze age differences in GLP-1 RA response across a population-based cohort of 26,442 persons in the upper midwest. The study will test three primary...
- The National Institute on Aging awarded Arizona State University $436,228 on June 1, 2026, under the Aging Research program (CFDA 93.866) to evaluate the impact of glucagon-like peptide-1 receptor agonists on sarcopenia in older adults. The research project will measure muscle mass and the mechanisms regulating muscle mass—including muscle protein synthesis and breakdown—using stable isotope tracer methodologies in older patients before and six months after GLP-1 RA treatment. The study will...
- The National Institute on Aging awarded the University of Pennsylvania $811,172 on September 1, 2026, under the Aging Research program (CFDA 93.866) to conduct a five-year prospective observational study testing whether economic scarcity affects medication adherence and uptake of preventive services among older adults with chronic disease. The research enrolls 400 adults aged 50 years or older who receive Supplemental Nutrition Assistance Program (SNAP) benefits and are prescribed once-daily...
- The National Institute on Aging awarded Fred Hutchinson Cancer Center $3.35 million on August 15, 2026, under the Aging Research program (CFDA 93.866) to develop personalized guidance for menopausal hormone therapy decision-making. The project will create risk scores combining clinical, demographic, and genetic factors to provide individualized estimates of outcome risk with and without menopausal hormone therapy, addressing seven key MHT-associated outcomes: breast cancer, colorectal cancer,...
- Federal Grant Award Summary The University of Florida, Division of Sponsored Research, received a $383,750 Project Grant award from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), effective August 15, 2025, through July 31, 2027. This research project focuses on characterizing age-related changes to the senescence-associated secretory phenotype (SASP) of thyroid tissue in papillary thyroid carcinoma (PTC). The deliverables include scientific research aimed...
- The National Institute on Aging awarded The Trustees of Columbia University in the City of New York $552,154 on February 1, 2026, under the Aging Research program (CFDA 93.866) to characterize hormone therapy use patterns in women with premature or early menopause, identify patient and physician factors associated with therapy initiation and continuation, and develop a dynamic risk prediction model to identify women at high risk for underuse. The project addresses an evidence gap: up to 3.1...
- The National Institute on Aging awarded The Rand Corporation $1.366 million on September 15, 2025, under the Aging Research program (CFDA 93.866) to conduct analyses of Medicare beneficiary access to medications for opioid use disorder and assess the impacts of state and federal policies on treatment disparities and health outcomes. The research examines barriers to access for the three FDA-approved medications to treat opioid use disorder: methadone, buprenorphine, and naltrexone. The study...
- The National Institute on Aging awarded Harvard Pilgrim Health Care, Inc. $706,310 on May 1, 2026, under the Aging Research program (CFDA 93.866) to conduct a longitudinal study examining the interplay among reproductive, molecular, and chronological age in relation to aging-related conditions in women. The study leverages existing high-quality data and biosamples from a well-phenotyped population of over 850 women followed from recruitment in early pregnancy in 1999–2002 for over two decades....
- The National Institute on Aging awarded the University of Southern California $5.945 million on September 1, 2026, under the Aging Research program (CFDA 93.866) to conduct the Alzheimer's Risk Intervention Trial with Estradiol (ARITE), a randomized, double-blinded, placebo-controlled investigation of menopausal hormone therapy effects on neuroimaging markers of Alzheimer's disease and related dementias risk in postmenopausal women. The trial enrolls 360 postmenopausal women and uses brain...
- The National Institute on Aging awarded the University of Florida $725,528 on September 1, 2026, under the Aging Research program (CFDA 93.866) to conduct research on resistance exercise training for older adults with obesity using GLP-1 receptor agonists. The project will evaluate whether progressive, moderate to high-intensity resistance training mitigates muscle loss and strength decline in older adults initiating GLP-1 receptor agonist therapy for obesity treatment. The research addresses...